Table 3.
The background factors on total costs used for the linear model
| Factor | Diagnostic perioda | 12-month perioda | ||
|---|---|---|---|---|
| Adjusted β (SE) or adjusted mean (SE) | p value | Adjusted β (SE) or adjusted mean (SE) | p value | |
| PET/CT | 0.081 | 0.516 | ||
| Yes | 8.47 (0.09) | 9.32 (0.06) | ||
| Gender | 0.216 | 0.314 | ||
| Male | 8.34 (0.06) | 9.28 (0.04) | ||
| Diagnosis | 0.289 | 0.324 | ||
| LVV | 8.31 (0.06) | 9.33 (0.04) | ||
| AAV | 8.43 (0.07) | 9.24 (0.05) | ||
| IgAV | 8.41 (0.08) | 9.31 (0.06) | ||
| CRPa | 0.04 (0.03) | 0.156 | − 0.04 (0.02) | < 0.05 |
| Diagnosis delaya | 0.05 (0.03) | < 0.05 | 0.02 (0.02) | 0.204 |
| Number of laboratory studiesa | 0.17 (0.04) | < 0.001 | 0.47(0.04) | < 0.001 |
| In-patient daysa | 0.59 (0.04) | < 0.001 | 0.52 (0.03) | < 0.001 |
PET/CT positron-emission tomography/computed tomography, AAV antineutrophil cytoplasmic antibody-associated vasculitis, IgAV IgA vasculitis and other small-vessel vasculitis, CRP C-reactive protein, β regression coefficient for a one-unit increase in continuous factors
aLog-transformed values were used in the linear modeling